Table 2 Study endpoints according to molecular genetic and clinical prognostic subgroups

Overall

23.1

(21.2, 25.4)

89.3%

(85.4, 92.2)

46.2%

(40.4, 51.8)

25.4%

(19.9, 31.3)

MGMT methylated

34.7

(27.0, 40.7)

94.5%

(88.8, 97.3)

66.7%

(57.5, 74.4)

46.4%

(35.8, 56.3)

MGMT un-methylated

19.8

(17.9, 21.7)

86.4%

(80.0, 90.8)

32.1%

(24.5, 9.9)

11.0%

(5.7, 18.2)

Gross total resection

25.4

(21.8, 28.2)

91.8%

(87.1, 94.8)

51.2%

(43.9, 58.1)

29.9%

(22.6, 37.5)

Partial resection

21.1

(19.1, 23.1)

85.0%

(77.2, 90.2)

37.7%

(28.6, 46.7)

18.0%

(10.5, 27.1)

KPS at baseline ≥ 90

23.7

(21.8, 26.7)

94.0%

(90.0, 96.4)

49.2%

(42.3, 55.8)

26.6%

(19.9, 33.8)

KPS at baseline < 90

19.8

(16.6, 23.9)

77.8%

(68.0, 84.9)

38.8%

(28.5, 49.0)

22.1%

(13.4, 32.2)

ALC > 800

23.6

(21.7, 28.2)

89.9%

(84.0, 93.7)

49.5%

(41.1, 57.4)

28.7%

(20.6, 37.3)

ALC ≤ 800

21.6

(19.9, 25.2)

88.7%

(82.8, 92.6)

43.3%

(35.4, 50.9)

22.2%

(15.0, 30.3)

Age < 50 years

26.2

(21.1, 31.5)

92.5%

(84.2, 96.6)

51.7%

(39.9, 62.3)

28.0%

(16.4, 40.8)

Age ≥ 50 years

22.4

(20.4, 24.1)

88.2%

(83.5, 91.7)

44.4%

(37.7, 50.8)

24.6%

(18.5, 31.2)